Purpose: Inter-subject variability in oral drug absorption is usually reported using bioavailabilty, which 69 has the components: fraction absorbed (fa), fraction passing the gut wall (fg) and fraction escaping 70 hepatic metabolism (fh). In this study, we sought to separate the absorption (fa*fg) and elimination (fh) 71 components of bioavailability to study variability of absorption and to investigate the effect of 72 formulations, gastric pH and food on absorption variability. 
Introduction

94
The terms absorption and bioavailability (F) are often used interchangeably (1) , though these are distinct 95 concepts. Indeed, whereas bioavailability is defined as the fraction of an oral dose administered that 96 low absorption and consequent variability in this parameter. In turn, understanding fa and its associated 121 inter-subject variability in the early stages of drug development provides an opportunity to understand 122 absorption mechanism, optimise formulation performance by increasing drugs solubility or dissolution 123 rate, and consequently to increase drug absorption. However, the effect of different formulations on 124 inter-subject variability is usually not assessed at such an early stage in the clinical development 125
process. 126
When analysing clinical pharmacokinetic data (as drug plasma concentrations), it is common to use 127 non-linear mixed-effect modelling (NLME) -the so-called "population approach" (FDA Guidance for 128
Industry Population Pharmacokinetics). The advantage of this modelling approach is the improvement 129 in underlying effects in drug performance which is important in understanding variability in population 130
One of the more difficult tasks for a modeller is to find an appropriate structural description of drug 132 absorption, as the population pharmacokinetic modelling approach should be executed while taking into 133 account the physicochemical properties of a drug, the physiology of the subject and the variability of 134 all the different mechanisms of absorption. The traditional models used to describe the absorption 135 process are simple and include a parameter describing the absorption rate (first or zero order absorption 136 rate constant), bioavailability and usually a lag time parameter characterizing any potential absorption 137 delay. Given the importance of characterizing absorption, more effort should be expended on 138 developing these models. 139
In this study, the well-stirred model was used to separate fh from fa*fg in place of bioavailability in 140 order to gain a better understanding of inter-individual variability in absorption from different 141 formulations in phase I/II clinical studies. The population approach allowed the determination of the 142 magnitude of inter-subject (individuals) variability. The population pharmacokinetics of four 143 compounds with different reported bioavailabilities (Table I) Physicochemical properties and pharmacokinetic parameters based on non-compartmental analysis for 163 each compound are specified in Table I . In addition, the plasma vs. time profiles on log scale of the four 164 compounds in the different formulations are presented in Figure 1 . Inter-subject variability in oral drug 165 absorption was investigated in relation to the effect of PR (prolonged release) formulation, gastric pH 166 and food effect and for the low, intermediate 1 and intermediate 2 compounds, respectively. Clinical 167 trials from phase I/II were incorporated in the analysis and fa*fg was estimated for the oral solution and 168 different formulations under the mentioned conditions. The number of subjects, demographics (age and 169 weight) and administered doses are listed in Table II . The IV data were analysed with first-order conditional estimation (FOCE) plus interaction (inter-238 individual and residual variability). For the IV data analysis, the ADVAN7 TRANS1 (General Linear 239
Model with Real Eigen value and estimation of Q and V PK parameters) subroutine in NONMEM was 240
used. 241
Once an adequate structural model was identified, the disposition parameters and its associated inter 242 subject variability were then fixed, on the assumption that absorption model mis-specification may 243 unduely influence disposition parameters when data were pooled. Additional (e.g. oral) data for each 244 formulation or condition (fast\fed) from different studies were pooled, and the absorption model was 245
developed. 246
The extraction ratio (ER) was calculated based on the intrinsic hepatic clearance (CLi) and liver blood 247 flow (FQ) and was further utilised to estimate fa*fg based on bioavailability (F1) NONMEM estimation 248 is the sum of squared deviations between the predictions and the observations. In NONMEM, the 274 objective function is -2 times the log of the likelihood. A difference in objective function value of 3.84 275 is considered to be significant at p<0.05 with one degree of freedom, based on chi squared distribution)); 276 successful covariance step; by examination of relative standard error values and goodness-of-fit plots. 277
Xpose (version 4.0) and R software (Version 3.1.1) were used for the graphical goodness-of-fit analysis. 278
A visual predictive check (VPC) was employed to characterize the model's simulation properties. The 279 final model was used to simulate 500 new datasets, based on the design of the original data set. For each 280 of the original data points, a 95% prediction interval was obtained by extracting the 2.5% and 97.5% 281 percentiles of their simulated distributions. These were then plotted against the observations using PsN 282 (Perl speaks NONMEM Version 3.5.3) and Xpose (version 4.0). 283
To estimate inter-subject variability, simulations using R in 1000 subjects were carried out to estimate 285 variance from the model, the square root of the variance being the standard deviation (using Multivariate 286
Normal Density and Random Deviates package to provide the density function and a random number 287 generator for the multivariate normal distribution with mean equal to mean and covariance matrix 288 sigma). The coefficient of variation (CV%) was then calculated by dividing the standard deviation by 289 the mean value (Table IV) . PsN was also used to run a nonparametric bootstrap of 200 iterations to 290 provide unbiased estimates of the standard errors and the 95% confidence intervals of the estimated 291 parameters ( Figures 4A, B and C) . The terms high and low variability refer to distributions that have 292 high and low coefficients of variation, respectively. Typically, a coefficient of variation of a 293 pharmacokinetic parameter of 10% or less is considered low, 25% is moderate, and above 40% is high 294 (9). 295
Results 297 298
The best fit for the disposition model for all four compounds was achieved with a three compartment 299 model. For high, intermediate 1, intermediate 2 and low bioavailability compounds, the OFV decreased 300 significantly, when changing from two compartments model to a three compartments model. In 301 addition, no significant improvement in fit with a four compartment model was observed for any 302 compound. A successful covariance step was observed for all structural models. Shrinkage percentages 303 are in the acceptable range (Table I , supplementary appendix). The disposition parameters of the final 304 structural model for all four compounds are presented in Table III . Reasonable goodness-of-fit plots 305
confirmed that the structural model adequately described the data (Figure 1, supplementary appendix) . 306
307
After fixing the disposition parameters and adding the oral data, estimations of fa*fg and ka (absorption 308 rate constant) were carried out by adding an absorption compartment. Improvement in fit using a lag-309 time was tested for oral solution formulations for all compounds, and appeared to improve the fit. 
324
fa*fg and inter-subject variability estimations for the different formulations presented in Table IV . For 325 the low bioavailability compound, fa*fg for the oral solution was estimated to be 33% with inter-subject 326 variability of 39% which increased when the compound was formulated as prolonged release 327 formulation (57%) and variability decreased to 15%. The effect of different forms of the active 328 ingredient (salt and base forms) on the inter-subject variability in absorption was investigated for 329 intermediate 1. fa*fg of the salt form increased compared to the base form although variability was 330 similar for both forms. However, under elevated gastric pH, inter-subject variability in fa*fg increased 331 for both forms. Food effect absorption was investigated for intermediate 2 compound when an oral 332 solution and a PR formulation were given under fasted and fed conditions. Positive food effect was 333 observed when oral solution was administered (increase of 16% in fa*fg) which diminished when the 334 PR formulation was administered. Inter-subject variability was similar across all formulations under 335 fed and fasted states (CV~30%). 336
Discussion 338
In this investigation, the "well stirred "model was successfully implemented in NONMEM analysis to 339 focus on the drug absorption and its associated inter-subject variability, and not overall bioavailability. 340
The high bioavailability compound was chosen as a control drug to confirm that the absorption values 341 generated by NONMEM with the fitted "well-stirred" model equations are valid. The absorption rate 342 constant was high for the oral solution, indicating that the compound is rapidly absorbed. 100% 343 absorption was estimated for the oral solution with short lag time. A relatively low inter-individual 344 variability was estimated for this compound (9%). 345
Effect of formulations on inter-subject variability (low bioavailability compound) 346
For the low bioavailability compound, the absorption rate was faster in the case of the solution compared 347 to the PR formulation (3.2 and 0.04 h -1 , respectively), with higher variability in the solution absorption 348 rate than in the solid dosage form. Low absorption was estimated for the oral solution and high 349 variability whereas the PR formulation absorption increased to 60% and corresponded inter-subject 350 variability decreased by more than half. The low absorption after oral solution administration (30%) 351 indicates fh is around 50%. Therefore, the low bioavailability in the case of the solution dosage form 352 can be attributed to both absorption and hepatic elimination. Inter-subject variability in absorption is 353 higher compared to the inter-subject variability in bioavailability (40% vs 26%), indicating absorption 354 process might be responsible for major differences between subjects. 355
Considering the physicochemical properties of this compound (Table I) , solubility or dissolution should 356 not be the rate-limiting step, as in its given dose it is expected to be completely dissolved in the GI 357 fluids. The increase in the absorption for the PR formulation might indicate a possible stability issue for 358 the drug in the upper part of the gastrointestinal tract. Allowing for a low dissolution rate in the upper 359 part of the gut will enable more of the drug to reach the lower parts of the gut, thus prolonging 360 absorption. In addition, no gut wall metabolism is expected based on clinical trial data that showed that 361 no effect on drug pharmacokinetics when co-administered with the P-gp inhibitor verapamil 362 (AstraZeneca data file).
The effect of gastric pH on inter-subject variability in absorption (intermediate 1 364 bioavailability compound) 365
Based on the absorption estimations for the oral solution for intermediate 1 compound (60%), fh 366 estimated at around 90%, indicating low hepatic extraction; therefore, the medium bioavailability can 367 be attributed to the decrease in absorption. Inter subject variability of the oral solution absorption was 368 lower compared to the inter-subject variability in bioavailability, but still classified as medium inter-369 subject variability (22% vs. 15%). The absorption of the base form did not differ from the oral solution 370 (~60%). 15% increase in the drug absorption for the salt form might indicate that the absorption is 371 solubility/dissolution rate-limiting. 372
The intermediate 1 compound is a weak base therefore, its solubility would be highly dependent on the 373 gastrointestinal pH, and drug precipitation might occur as a consequence of the pH increase from acidic 374 in the stomach (especially in the fasted state) to near-neutral in the small intestine (10). It seems that 375 the salt formulation managed to minimize precipitation, and yielded a super-saturated state for a longer 376 period of time in order to allow longer absorption. To emphasise that, the absorption of the base and 377 the salt forms decreased 4 and 2 folds respectively, at elevated gastric pH. At elevated gastric pH, the 378 compound solubility in the gastric fluid is low, and almost all the drug would be emptied into the 379 duodenum from the stomach in the undissolved form. Both the rate and extent of absorption are 380 therefore limited by intestinal drug dissolution. The inter-subject variability estimated herein was similar for all formulations around 15%, and 388 increased under elevated gastric pH conditions. The increase in solubility of the drug using the saltformation did not affect the inter-subject variability. The medium inter-subject variability might mask 390 the increase in absorption (only 10%) when the drug was administrated in the salt form. In the case of 391 elevated gastric pH, the differences in gastric pH due to omeprazole administration can explain the 392 increase in variability. 393 394
The effect of food effect on inter-subject variability in absorption (intermediate 2 395 bioavailability compound) 396
For intermediate 2, the ka value for the oral solution was relatively high compared to the PR formulation, 397 indicating a slow release of the drug from the tablet matrix in the GI tract, and hence slow absorption. 398
The variability in the rate of absorption was higher in the case of the solid dosage forms as compared 399 to the solution, which might be attributed to the differences in the disintegration and dissolution of the 400 drug resulting from the difference between individual GI physiology. With regards to absorption, 401 solution absorption in the fasted state was estimated 60% and increased in the fed state (77%). 402
Comparing the PR formulation and the solution in the fasted state, it can be seen that absorption 403 increased by 10%. In addition, no food effect was observed for the PR formulation (71% vs. 68% under 404 fast and fed states respectively). 405
The physiology of the gastrointestinal tract changes in the fed state, and may consequently affect drug 406 absorption. The remarkable changes in the stomach under the fed state notably include a rise in gastric 407 pH thanks to buffering and dilution effects, along with an increase in the gastric fluid volume and a 408 decrease in gastric emptying time. In the small intestine, an increase in bile salt concentration, decrease 409 in fluid volumes and in some cases inhibition of CYP enzymes and efflux transporters are expected (5). 410
Since intermediate 2 is a free base, it would be expected to have high solubility in the gastric fluids, and 411 its solubility should not decrease significantly in the administered clinical dose in the intestine. Another 412 explanation is the drug degradation in low pH conditions which might explain the increased absorption 413 under fed state. In vitro studies have shown to support this hypothesis (11). In the fed state, both the 414 elevated gastric pH and the low retention time in the stomach might contribute to the drug stability, andtherefore more drug arriving to the small intestine that is available for absorption. In addition, it might 416 be that an increase in bile salt concentration and gastric fluid volumes might have a positive food effect 417 on the drug absorption under fed conditions. The food effect vanished in the case of the prolonged 418 release formulation. Thanks to a slower dissolution in the stomach, less of the drug is deemed 419
